What Insurance Covers Zepbound in 2026?

In 2025, several major pharmacy benefit managers (PBMs) and insurers removed or restricted Zepbound coverage due to its cost and the surge in demand. CVS Caremark, one of the largest PBMs, removed Zepbound from its standard formulary in July 2025, instead preferring a competing drug (Wegovy) as the covered option.

The demand for Zepbound is huge, with 25,000 new prescriptions per week at the end of 2023. However, insurance coverage has not kept up with this interest. As of now, over 109 million people have no insurance coverage for Zepbound.

This gap between medical need and coverage is causing frustration for patients and doctors alike, and it’s a big reason why we need to carefully examine what health insurance plans cover Zepbound in 2026.

Which insurance plans cover Zepbound for weight loss?

Coverage for Zepbound largely depends on what kind of insurance you have. Below are the major categories and the coverage situation for each in 2026. Keep in mind that within each category, specific coverage can vary widely by insurer and even by plan.

1. Employer-Sponsored Health Plans (Commercial Insurance)

Most employer insurance plans do not automatically cover Zepbound, but if you are with a large employer, there’s a decent chance the benefit is at least offered. Always check with your HR or insurance about coverage specifics.

Large employers vs. mid-size and small employers

If you get your insurance through a large employer, you have the best odds of Zepbound coverage.

According to a Kaiser Family Foundation survey, only 19% of employers with 200 or more workers cover GLP-1 drugs for weight loss in their main health plan in 2025. But among firms with at least 5,000 employees, 43% include these medications. This was an increase from the year before, when only 28% of these large employers offered coverage.

Another survey in late 2025 by Brown & Brown also found that 48% of employers now offer coverage for GLP-1 drugs for weight loss, and about 89% of those plan to continue covering them into 2026.

However, more than 60% of employers that offer coverage place extra rules on who can get these medications. Almost half (49%) go beyond standard requirements like prior authorization. For example, 38% require participation in a lifestyle or behavior-change program. Another common restriction limits prescribing to a specific provider or a single approved prescriber.

So in practice, coverage does not guarantee access. Many employees technically have GLP-1 coverage, but still do not qualify under their employer’s rules.

State-regulated vs. self-funded plans

Large employers often have self-funded plans, which means state insurance mandates do not apply to them.

In a self-funded plan, the employer pays medical claims directly. These plans are governed mainly by federal law (ERISA), not state insurance law. Because of that, state mandates, even strong ones, do not apply. So a large employer can legally exclude GLP-1 weight-loss drugs, even if the state requires coverage.

So, for example, even though North Dakota now requires GLP-1 coverage under state insurance rules, most large employers are exempt because their self-funded health plans are not subject to state mandates.

Smaller employers and individual plans are state-regulated. So, if you’re in a state that requires coverage of an anti-obesity medication, like North Dakota, that will apply to individual and small-group plans in that state.

2. Individual & ACA Marketplace Plans

If you purchased your insurance on the ACA Marketplace (Healthcare.gov or a state exchange) or have an individual/family policy, unfortunately, coverage for Zepbound is rare in this segment. According to industry analyses, fewer than 1% of marketplace insurance plans covered obesity medications in 2024.

However, there are a couple of exceptions emerging.

North Dakota became the first state to mandate that all state-regulated health plans, including individual and small-group plans, cover GLP-1 and GIP obesity medications by adding them to the state’s essential health benefits list. So if you live in North Dakota and buy an ACA plan, it should cover Zepbound or at least one medication in that class.

West Virginia has also been discussing a similar requirement, though it wasn’t yet enacted as of late 2025. A few other states, like Illinois, Connecticut, and Georgia, have considered adding obesity drugs to required coverage lists or have mandated coverage in certain markets, so it’s worth checking your state’s recent legislation.

California’s AB 575, for instance, was aimed at requiring at least one anti-obesity medication be covered on group and individual plans, but its status is unclear for 2026.

Always research if your state has any specific laws.

3. Medicare (Part D and Medicare Advantage)

Medicare’s coverage of Zepbound is a bit complex. Under the current law, Medicare Part D does not cover drugs used for weight loss. One important nuance is that if a drug has another FDA-approved indication, Medicare can cover it for that purpose.

Zepbound received FDA approval in December 2024 for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. This is distinct from the weight-loss indication. So, Medicare Part D technically could cover Zepbound if prescribed for OSA in an obese patient.

The good news is that in late 2025, the administration (via CMS) launched the BALANCE demonstration model. It’s a federal pilot program designed to make certain GLP-1 drugs and lifestyle programs more affordable and more available for people on Medicare and Medicaid.

What the program does is that CMS, the federal agency that runs Medicare and Medicaid, will step in and negotiate:

• • Drug prices
  • Coverage conditions
  • Access rules

This is meant to lower costs and make plans more willing to cover GLP-1s, paired with nutrition and lifestyle support.

Keep an eye on your plan’s communications or call them in mid-2026 to ask if they have started covering Zepbound under the new CMS model. If not, during Medicare open enrollment for 2027, you might look for a plan that is participating in the obesity drug coverage demo, if that information becomes available.

In summary, until policy changes, Medicare will deny Zepbound for weight loss but may allow it for OSA or other non-weight indications with proper documentation.

4. Medicaid

Medicaid coverage for Zepbound is highly variable since each state sets its own coverage policies. To find out if your state Medicaid covers any weight loss medications, you can usually find this in a Medicaid pharmacy FAQ or formulary document, or by asking your healthcare provider to check. If it’s covered, prepare the needed requirements and work with your doctor on the prior authorization paperwork.

In late 2025, about 16 state Medicaid programs cover GLP-1 medications for obesity treatment. However, four states (California, New Hampshire, Pennsylvania, and South Carolina) dropped coverage for obesity treatment due to budget strain.

With those changes, only 13 states still cover GLP-1 drugs for obesity under Medicaid as of January 2026. These include states like:

• • Utah
  • Minnesota
  • Wisconsin
  • Michigan
  • Kansas
  • Missouri
  • Mississippi
  • Tennessee
  • North Carolina
  • Virginia
  • Delaware
  • Massachusetts
  • Rhode Island

The new federal plan (the BALANCE model) also invites state Medicaid programs to participate, meaning states can choose to opt in to get the discounted pricing and cover GLP-1 drugs for obesity starting mid-2026. This could be a potential turning point for Medicaid coverage if states participate, since it lowers cost barriers. We might see more states adding coverage as a result.

5. TRICARE and Other Government Insurance (VA, Federal Employee Program)

For those on military or other federal insurance programs:

TRICARE (Military Insurance)

TRICARE limits coverage of weight-loss medications to specific groups of beneficiaries, and eligibility depends on both the medical indication and plan type.

Coverage for weight-loss drugs such as Saxenda, Wegovy, Zepbound, Qsymia, phentermine, and Contrave is available only if all of the following apply:

• • You are enrolled in TRICARE Prime, TRICARE Select, or a qualifying premium-based TRICARE plan, including:

• • • • TRICARE Young Adult
      • TRICARE Reserve Select
      • TRICARE Retired Reserve
      • Continued Health Care Benefit Program

• • You meet TRICARE’s medical eligibility requirements
  • The medication is prescribed by a TRICARE network provider
  • A prior authorization request is submitted and approved

Weight-loss drug coverage is not available to beneficiaries enrolled in TRICARE For Life or those who receive care through direct care only arrangements.

To verify whether a medication is covered and what requirements apply, use the TRICARE Formulary Search Tool and download any required prior authorization forms.

VA (Veterans Affairs)

The VA provides weight management medications to eligible Veterans who meet medical and program requirements. To qualify, a Veteran must first take part in a Comprehensive Lifestyle Intervention (CLI). This program addresses:

• • Nutrition and diet
  • Physical activity
  • Behavioral and lifestyle changes

At many VA facilities, this requirement is met through participation in the MOVE! Weight Management Program.

Medication will only be considered after enrollment in a CLI and once the Veteran shows meaningful participation. The VA offers five FDA-approved medications for chronic weight management, selected based on individual assessment.

Those that are on the VA National Formulary and require facility-level prior authorization include:

• • Orlistat (Xenical)
  • Phentermine/topiramate (Qsymia)
  • Bupropion/naltrexone (Contrave)

Those that are non-formulary and subject to additional approval include:

• • Tirzepatide (Zepbound)
  • Semaglutide (Wegovy)

Note that it is still handled on a case-by-case basis. At VA San Diego, for example, injectable weight loss medications are limited to approved tiers (Tier 1a, 1b, and 2a), primarily for patients with a BMI of 40 or higher.

Federal Employee Health Plans (FEHB)

If you’re a federal employee/retiree under the FEHB program, coverage will depend on which carrier and plan you have. FEHB includes Blue Cross federal plans, GEHA, Aetna federal plans, and more.

For instance, GEHA (a popular FEHB plan) explicitly announced it will cover Zepbound in 2026, but only if you get special approval. For all GEHA plans in 2026 (High, Standard, HDHP, Elevate Plus, and Elevate), Zepbound is non-formulary. That means it’s not on the plan’s standard drug list, and coverage is exception-based.

To have Zepbound covered for weight loss in 2026, your doctor must request a Formulary Exception, which is stronger than a regular prior authorization. Your provider must also explain why Zepbound is medically necessary. The plan then reviews the request on a case-by-case basis.

Because FEHB is a competitive program, some plans are using coverage of weight loss meds as a selling point. If your current FEHB plan doesn’t cover Zepbound and you need it, you might switch during Open Season to one that does.

How to know if you’re eligible for Zepbound coverage

Eligibility for Zepbound involves two aspects:

Medical Eligibility for Zepbound

This is based on your BMI and health conditions. The FDA approval criteria are:

• • BMI of 30 or higher (obesity), OR

• • BMI of 27 or higher plus at least one weight-related condition, such as type 2 diabetes, hypertension (high blood pressure), dyslipidemia (high cholesterol), obstructive sleep apnea, or heart disease.

If you fall into one of those categories, you are a candidate for Zepbound. If your BMI is below 27, you generally would not be prescribed Zepbound for weight loss, as it’s not indicated for people who are only mildly overweight. Similarly, if you have a BMI of 28 but no comorbidities, most doctors would not start Zepbound unless perhaps you have other compelling risk factors.

Also note that Zepbound is approved for adults aged 18 and over. It’s not approved for pediatric use as of 2026, unlike Wegovy, which has a teen indication.

There are also a few medical contraindications that might make you ineligible medically, regardless of insurance. For example, Zepbound carries a warning about the risk of a rare thyroid cancer (medullary thyroid carcinoma) seen in rodents. It’s contraindicated if you or a family member has a history of certain endocrine tumors (MEN2 syndrome). Also, if you have active pancreatitis, gallbladder disease, or certain other conditions, doctors might avoid Zepbound.

Assuming you meet the BMI and health criteria and have no major contraindications, a doctor can prescribe Zepbound.

Insurance Approval Criteria (Prior Authorization Requirements)

Every insurance plan that covers Zepbound will have a prior authorization (PA) process. This means your doctor must submit a request to the insurance with information about your case, and the insurer will approve or deny coverage based on their criteria.

While criteria differ by insurer, here are common elements almost all plans require for Zepbound in 2026:

• • BMI and diagnosis documentation
  • Previous weight loss efforts
  • Step therapy or alternatives
  • Clinical justification
  • Specialist involvement (like an endocrinologist or obesity medicine specialist)

Once the prior authorization is submitted, the insurance will review it. If everything lines up, they will approve coverage, typically for an initial 3-6 months. They often want to see that you respond to the medication (e.g., lose a certain percentage of weight) to continue coverage beyond a certain time.

For example, an insurer might approve 6 months of Zepbound, then require your doctor to attest that you lost at least 5% of your starting weight by that point to approve further refills. This is to ensure the drug is effective for you.

How to check if your insurance covers Zepbound

Given the complexity, how do you find out if your specific insurance plan will cover Zepbound? Here are some steps and tips:

Review your plan’s formulary or drug list

This is the document that lists all medications and whether they are covered and at what tier. You can usually find it on your insurer’s website or by logging into your member portal. Look up “Zepbound” or “tirzepatide”. If it’s listed, see if it’s under a particular tier (e.g., Tier 3 or Tier 4 specialty) and if there are notes like “PA” (prior authorization required) or “ST” (step therapy) next to it.

Some formularies might not list the brand name if it’s new. Check under the diabetes section for tirzepatide or even under “Mounjaro” (the diabetes version) to see if there’s a clue. If it says “Excluded” or doesn’t appear at all, that’s a sign it might not be covered for weight loss.

However, absence from a formulary doesn’t always mean no. It could mean they haven’t updated it yet. Also note if it’s listed with a restriction like “only covered for diagnosis of type 2 diabetes” or “not covered for weight management.”

Call your insurance customer service

The simplest way is often to call the number on your insurance card and ask directly: “I want to know if my plan covers the medication Zepbound for weight loss.”

Prepare for some front-line representatives to give unclear answers, because this is a nuanced question. Emphasize that you want to know about your specific policy’s coverage. They might check a system and tell you, “It requires prior authorization” or “It’s not on the formulary.”

If they say it’s excluded, ask if that is for all diagnoses or just for obesity. Sometimes reps will say, “We cover it for sleep apnea, but not for obesity.” Any information they give, note it down. If the rep seems unsure, you can ask for a pharmacist or a supervisor, or call back to get a different agent.

Another approach is to specifically ask: “Can you run a test claim?” Some insurance helplines have the ability to do a test claim for a medication with your info to see if it would be rejected or what it would cost.

Use the insurer’s online tools

Some insurers have online portals where you can look up drugs and see coverage status. For example, UnitedHealthcare/Optum or Aetna has searchable databases for members. Type in “Zepbound” and see what comes up.

Additionally, Eli Lilly offers a website to check coverage. It might require you to input your insurance information, and it will then tell you if you’re covered and provide an estimate of cost. This can be handy, though it’s based on available data and not a guarantee.

Ask your doctor’s office to check

Physicians, especially specialists, often have staff who deal with insurance authorizations regularly. They might know from experience which local insurers have been approving or denying Zepbound. Some doctors might do a quick check by sending a prescription to the pharmacy and seeing if the pharmacy can process it. If the pharmacy insurance system rejects it with a message like “not covered,” they’ll know.

Look at your policy documents

Sometimes, the detailed plan document will state exclusions. Search the PDF for terms like “weight” or “obesity.” If you find a clause like “Drugs for weight reduction are not covered,” then you know it’s an exclusion. If you see a specific mention like “Anti-obesity medications are covered with prior authorization,” that’s a green light.

What to do if your insurance denies Zepbound coverage

Here’s a plan of action if you are denied:

1. Understand the reason for denial

When your insurance denies a prior authorization request, they will give a reason. Common denial reasons include:

• • “Benefit exclusion – weight loss drugs not covered under plan.” (This means the plan doesn’t cover it by design.)

• • “Does not meet criteria – patient did not attempt lifestyle modifications” or “BMI criteria not met.” (This means something in the documentation didn’t satisfy their requirements.)

• • “Formulary exclusion – drug not on formulary.” (Similar to a benefit exclusion, but sometimes can be appealed if an alternative is on formulary.)

• • “Step therapy required – must try X first.” (They might want you to try the preferred alternative.)

The denial letter or message should outline this. If it’s a straight exclusion (no weight loss drugs covered), your approach might be to request an exception or appeal on medical necessity grounds. If the criteria are not met, you can often correct that by providing more info or fulfilling that requirement. For example, document the 6-month diet after the fact, or reapply once you’ve tried the alternate drug.

2. File an appeal (or a formulary exception request)

You have the right to appeal any insurance denial. In fact, over 80% of prior authorization denials that were appealed were overturned in 2022. Unfortunately, only 18% of physicians said they always appeal when a prior authorization is denied. So be among those who do, because your chances are good if you have a legitimate need.

The appeal process usually involves:

• • A letter explaining why Zepbound is medically necessary for you. This letter should address the reason for the denial specifically. For example, if the plan excludes weight loss drugs, the doctor should emphasize your comorbid conditions and maybe cite medical guidelines that obesity is a disease requiring treatment. If the denial was because “try Wegovy first,” the letter could explain why Wegovy isn’t suitable.

• • Supporting documentation, such as doctor’s notes, clinical studies if relevant, or a personal statement. Some patients attach evidence like a body composition analysis or a letter explaining how obesity affects daily life, anything to humanize the request.

• • Sending the appeal to the insurer’s appeals department. Ensure it’s sent within the deadline, usually 30 or 60 days from denial.

Many insurers have multiple levels of appeal. Use all levels available if needed. Often, denials get overturned at the first or second appeal if the justification is strong.

3. Explore the OSA coverage pathway

As discussed earlier, if your plan excludes weight loss treatment but you have another condition like obstructive sleep apnea (OSA), talk to your doctor about leveraging that. Since Zepbound is FDA-approved for OSA in obese patients with moderate-to-severe sleep apnea, an appeal could be framed around that indication.

This approach has helped some patients get coverage even when weight loss is excluded. Do note, you truly should have the condition. If you snore or have risk factors, maybe getting evaluated for sleep apnea is worthwhile, usually diagnosed via a sleep study and AHI score.

Bottom line

Coverage for Zepbound is changing as more insurers begin to treat obesity as a chronic condition. Not all plans cover it yet, but growing demand is expanding access. Check your benefits, talk with your provider about your treatment goals, and work with your insurer. Understanding your options improves your chances of getting coverage.

Frequently Asked Questions

Sources

Office of the Commissioner. (2023, November 8). FDA approves new medication for chronic weight management. U.S. Food And Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management

Wingrove, P. (2024, January 8). Lilly CEO says weight-loss drug Zepbound weekly prescriptions hit 25,000 in December. Reuters. https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-ceo-says-weight-loss-drug-zepbound-weekly-prescriptions-hit-25000-december-2024-01-08/

Nguyen, A., PhD. (2026, January 12). LIVE Updates: Insurance coverage for GIP and GLP-1 agonists like Zepbound & Wegovy in 2025. GoodRx. https://www.goodrx.com/healthcare-access/research/tracking-insurance-coverage-weight-loss-meds

Ruble, J. (2025, October 27). States push forward on insurance mandates for GLP-1 and obesity treatments. Pharmacy Times – Pharmacy Practice News and Expert Insights. https://www.pharmacytimes.com/view/states-push-forward-on-insurance-mandates-for-glp-1-and-obesity-treatments

Perspectives from employers on the costs and issues associated with covering GLP-1 agonists for weight loss – Peterson-KFF Health System Tracker. (2026, January 12). Peterson-KFF Health System Tracker. https://www.healthsystemtracker.org/brief/perspectives-from-employers-on-the-costs-and-issues-associated-with-covering-glp-1-agonists-for-weight-loss/

Starner, T. (2025, December 17). GLP-1 popularity primed to be a big benefits challenge in 2026. HR Executive. https://hrexecutive.com/emerging-glp-1-drugs-are-reshaping-employers-2026-priorities/

Brown & Brown. (2025, December 1). Brown & Brown Employer Health and Benefits Strategy Survey | 2026 Edition – Brown & Brown. Brown & Brown. https://www.bbrown.com/us/insight/employer-health-and-benefits-strategy-survey-2026/

Office of the Commissioner. (2024, December 20). FDA approves first medication for obstructive sleep apnea. U.S. Food And Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea

BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive HEalth) Model | CMS. (n.d.). https://www.cms.gov/priorities/innovation/innovation-models/balance

Chatlani, S. (2025, November 28). States retreat from covering drugs for weight loss. Stateline. https://stateline.org/2025/11/28/states-retreat-from-covering-drugs-for-weight-loss/

Williams, E. (2026, January 16). Medicaid coverage of and spending on GLP-1s. KFF. https://www.kff.org/medicaid/medicaid-coverage-of-and-spending-on-glp-1s/

Commonwealth of Massachusetts. (2025, June 10). CVS Caremark decides to remove Zepbound from CVS Caremark formulary. Mass.gov. https://www.mass.gov/news/cvs-caremark-decides-to-remove-zepbound-from-cvs-caremark-formulary

673rd Medical Group – Joint Base Elmendorf-Richardson. (n.d.). TRICARE Coverage of Weight Loss Medications: What To Know. https://elmendorfrichardson.tricare.mil/News-Gallery/Articles/Article/4266447/tricare-coverage-of-weight-loss-medications-what-to-know

MOVE! weight management | VA San Diego health care | Veterans Affairs. (2025, June 2). Veterans Affairs. https://www.va.gov/san-diego-health-care/programs/move-weight-management/

Pearson SD, Whaley CM, Emond SK. Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US. J Comp Eff Res. 2025 Sep;14(9):e250083. doi: 10.57264/cer-2025-0083. Epub 2025 Jul 11. PMID: 40641455; PMCID: PMC12403326.

American Medical Association & American Medical Association. (2024, October 3). Over 80% of prior auth appeals succeed. Why aren’t there more? American Medical Association. https://www.ama-assn.org/practice-management/prior-authorization/over-80-prior-auth-appeals-succeed-why-aren-t-there-more